beta-hydroxyisovaleric acid
β-Hydroxy β-methylbutyric acid (HMB), otherwise known as its conjugate base, β-hydroxy β-methylbutyrate, is a naturally produced substance in humans that is used as a dietary supplement and as an ingredient in certain medical foods that are intended to promote wound healing and provide nutritional support for people with muscle wasting due to cancer or HIV/AIDS. In healthy adults, supplementation with HMB has been shown to increase exercise-induced gains in muscle size, muscle strength, and lean body mass, reduce skeletal muscle damage from exercise, improve aerobic exercise performance, and expedite recovery from exercise. Medical reviews and meta-analyses indicate that HMB supplementation also helps to preserve or increase lean body mass and muscle strength in individuals experiencing age-related muscle loss. HMB produces these effects in part by stimulating the production of proteins and inhibiting the breakdown of proteins in muscle tissue. No adverse effects from long-term use as a dietary supplement in adults have been found. — Wikipedia
Clinical trial activity
22 trials · 26 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2008 (NCT00874575)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaΒ-Hydroxy β-methylbutyric acid ↗
- WikipediaBeta-Hydroxy beta-methylbutyric acid ↗
Also known as
- 3-hydroxy-3-methylbutyric acid
- 3-hydroxyisovaleric acid
- beta hydroxy beta methylbutyrate
- beta-hydroxy beta-methylbutyrate
- beta-hydroxy beta-methylbutyrate
- beta-hydroxy-beta-methylbutyrate
- beta-hydroxy-beta-methylbutyrate
- beta-hydroxy-beta-methylbutyrate
- beta-hydroxyisovaleric acid
- beta-hydroxymethylbutyrate
- hmb-d6
- β-hydroxy-β-methylbutyrate
- β-hydroxy-β-methylbutyrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03692507 | Phase 1 | Nov 1, 2018 | California State University, Fresno, University of California, San Francisco |
| NCT03628365 | N/A | Sep 17, 2018 | Texas A&M University, University of Lausanne |
| NCT03464708 | Phase 2 | Jun 18, 2018 | University of London |
| NCT03404271 | N/A | Jan 17, 2018 | Dymatize Enterprises, LLC, Metabolic Technologies, Texas Tech University |
| NCT03071354 | N/A | Apr 1, 2017 | Wake Forest University |
| NCT02679742 | Phase 2 | Mar 1, 2017 | Institut Hospital del Mar d'Investigacions Mèdiques |
| NCT03018496 | N/A | Jan 1, 2017 | University of Nottingham |
| NCT03151291 | N/A | Dec 1, 2016 | University of Erlangen-Nuremberg |
| NCT02762968 | N/A | Apr 1, 2016 | Metabolic Technologies, University of Central Florida |
| NCT02717013 | N/A | Mar 1, 2016 | Iowa State University, Metabolic Technologies |
| NCT02602561 | N/A | Nov 1, 2015 | Iowa State University, Metabolic Technologies |
| NCT02503007 | N/A | Jul 1, 2015 | International Diabetes Federation, Koach Sport and Nutrition, Metabolic Technologies |
| NCT02118181 | N/A | Feb 1, 2014 | University of Padova |
| NCT01840098 | N/A | Jan 1, 2014 | Aarhus University |
| NCT02048397 | N/A | Sep 1, 2013 | Andaluz Health Service, Government of Spain |
| NCT01941368 | N/A | Sep 1, 2013 | Metabolic Technologies, University of Central Florida |
| NCT04001907 | N/A | Apr 30, 2013 | University of The West Indies |
| NCT01793779 | N/A | Dec 1, 2012 | Metabolic Technologies |
| NCT01837238 | N/A | Nov 1, 2012 | University of Illinois |
| NCT01508338 | N/A | Jan 1, 2012 | Metabolic Technologies, University of Tampa |